Speciality: Endocrinology
Description:
A warm welcome to all the medical practitioners in this interesting session of biosimilar insulin Glargine which is a product of Biocon.
Insulin is a hormone secreted from pancreas that helps blood sugar to enter the body's cells so it can be used for energy. Insulin also signals the liver to store blood sugar for later use. It is one of the important components that helps in controlling diabetes in patients.
The speakers Dr. Sunil Gupta, Dr. Anil Bhansali and panel has provided an elaborative knowledge on biosimilar insulin Glargine in the management of diabetes in patients.
Biosimilar insulins are manufactured in living organisms (e.g., yeast and bacteria) to produce large quantities of the product, which limits the ability to manufacture exact replicas of original biological medications. Insulin glargine is a synthetic version of human insulin that is FDA approved to treat adults and children. It is long-acting with the ability to control sugar all day long.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
2.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
3.
Study finds 10% of pediatric blood cancers may stem from medical imaging radiation
4.
For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.
5.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
1.
Case Study: Artificial Intelligence in Early Cancer Detection
2.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
3.
What is Mullerian and How Does it Affect Your Health
4.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
5.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation